Clinical Trial Update: MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of the MDX-060 monoclonal antibody in patients with refractory or relapsed lymphoma has completed, according to the update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• MDX-060

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lymphoma | Phase 1, Phase 2 | Status: COMPLETED